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Background: The aim of the study was to identify, interpret, and compare the current
perspectives of regulatory agencies in six member countries of BRICS-TM (Brazil, Russia,
India, China, South Africa, Turkey, and Mexico) on the different criteria used for biosimilar
development and marketing authorisation process.
Methods: A semi-quantitative questionnaire was developed covering the organisation
of agency, biosimilar development criteria and marketing authorisation process and
sent to seven regulatory agencies covering the BRICS-TM countries. All data was kept
anonymous and confidential. Data processing and analysis was carried out; descriptive
statistics were used for quantitative data and content analysis was employed to generate
themes for qualitative data.
Results: Out of the seven regulatory agencies included in the study, six representatives
provided the responses. The perspectives of these six regulatory agencies varied on
a number of aspects relating to the review criteria for biosimilar development and
licencing process. The most prevalent model for data assessment is the “full review”
of a marketing authorisation application. There is lack of a standard approach across
the agencies on sourcing of the reference biological product, in vivo toxicity studies and
confirmatory clinical studies. Most agencies restrict interaction with biosimilar developers
and any scientific advice is non-binding. The marketing authorisation approval depends
on scientific assessment of the dossier, sample analysis and GMP certification. The
agencies do not issue any public assessment report specifying the summary basis of
biosimilar approval.
Conclusion: Regulatory agencies across the six emerging economies are steadily
improving the regulatory mechanism in the area of biosimilars. However, there remains
scope for increasing the effectiveness and efficiency of the processes by encouraging
Rahalkar et al. Biosimilar Regulations in Emerging Economies
open and transparent interaction with developers, adopting a flexible approach toward
accepting advanced analytical data in lieu of clinical studies and enhancing regulatory
reliance amongst agencies. This will help to simplify the new biosimilar development
programmes and make them more cost-effective.
Keywords: BRICS-TM, biosimilar, emerging economies, marketing authorisation, regulatory agency
INTRODUCTION
Emerging economies represent 70% of the world population
accounting for a 31% share of global GDP and more than 30%
of pharmaceutical spending (1). In addition, they account for
one-third of the global growth in drug demand, with annual
growth rate of 5–8% (2). Biosimilars, which account for 28%
of the global pharmaceutical market have the potential to
significantly boost treatment options and hence are expected
to play an important role in the pharmaceutical market
(3). Emerging economies with low biologic-treatment rates
and affordability barriers present attractive opportunities for
biosimilars (4). However, marketing authorisations of these
much-needed products are often delayed as manufacturers
face challenges of multiple regulatory requirements to register
products in different countries (5, 6). It is encouraging to note
that the regulatory approval pathways for biosimilars applied by
the major regulatory agencies worldwide are, to a broad degree,
scientifically aligned (7). However, owing to regional differences
in healthcare priorities, policies, and resources, some important
regulatory inconsistencies are evident in emerging economies.
Some of these challenges such as lack of step wise approach,
Abbreviations: ANVISA, Agência Nacional de Vigilância Sanitária; BDEA,
Biosimilar Development, Evaluation and Authorisation; BRDD, Biologic and
Radiopharmaceutical Drugs Directorate; BRICS-TM, Brazil, Russia, India, China,
South Africa, Turkey, Mexico; B.Sc., Bachelor of Science; CDSCO, Central Drugs
Standard Control Organisation; CECMED, The Centre for State Control on
the Quality of Drugs; CEO, Chief Executive Officer; CLA, Central Licencing
Authority; CIRS, Centre for Innovation in Regulatory Science; CMC, Chemistry,
Manufacturing and Control; COVID, Corona virus; COFEPRIS, Comisión Federal
para la Protección contra Riesgos Sanitarios; COVID-19, Corona virus disease;
CPP, Certificate of Pharmaceutical Product; CTA, Clinical Trial Application;
DBT, Department of Biotechnology; EC, Ethics Committee; ECDA, European
Chronic Disease Alliance; EMA, European Medicines Agency; EU, European
Union; GDP, Gross Domestic Product; GMP, Good Manufacturing Practices;
ICH, The International Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use; IGBA, International Generic and Biosimilar
Medicines Association; MAA, Marketing Authorisation Applications; MD, Doctor
of Medicine; MHRA, Medicines and Healthcare products Regulatory Agency;
MoH, Ministry of Health; NDCTR, New Drugs and Clinical Trial Rules; NMC,
New Molecule Committee; NMPA, National Medical Products Administration;
PAHO, Pan American Health Organisation; PAR, Public Assessment Report; PD,
Pharmacodynamics; PharmD, Doctor of Pharmacy; PhD, Doctor of Philosophy;
PIC/S, Pharmaceutical Inspection Co-operation Scheme; PK, Pharmacokinetic;
PMDA, Pharmaceuticals and Medical Devices Agency; RBP, Reference Biological
Product; RCGM, Review Committee on Genetic Manipulation; SAHPRA, South
African Health Products Regulatory Agency; SBP, Similar Biotherapeutic Product;
SEC, Subject Expert Committee; SEPB, Subcommittee on evaluation of biotech
products; TGA, Therapeutic Goods Administration; TITCK, Türkiye Ilaç ve
Tibbi Cihaz Kurumu; US, United States; USFDA, United States Food and
Drug Administration; WHO, World Health Organisation; ZaZiBoNa, Zambia,
Zimbabwe, Botswana, Namibia.
difference in selection and sourcing of Reference Biological
Product (RBP), regulatory expectations of clinical efficacy trial
design and lack of transparency toward interchangeability,
switching and substitution norms, have been identified (8).
Inevitably, lack of standardised regulatory processes would
hamper the growth of biosimilars in these countries (9). Thus,
it is of paramount importance to evaluate the framework
for biosimilar development and approval processes in these
emerging economies.
In the last 2 decades, the mature regulatory agencies, in
particular in ICH jurisdictions, have made significant progress
toward establishing, revising, and updating biosimilar guidelines
to match the dynamic innovation in biotechnology. However,
there remains scope for improvement in establishing regional
standardisation for regulatory requirements of biosimilar
development and approval process.
The main objectives of the study were to:
• evaluate and compare technical capabilities of the six
regulatory agencies of the emerging economies in the area
of biosimilars,
• identify similarities and differences in regulatory requirements
of biosimilar development criteria i.e., biosimilarity
principles, comparative studies including physicochemical
characterisation, non-clinical, and clinical studies,
• evaluate and compare “must submit documents” as part of
biosimilar application for marketing authorisation in these six
emerging economies,
• map the biosimilar marketing authorisation approval pathway
specifically for key milestones, scientific advice meetings,
clinical trial mandates, and backlogs.
METHODS
Study Participants
The regulatory authorities included in this study were those
which are part of the BRICS-TM grouping. This refers to the
countries of Brazil, Russia, India, China, South Africa, Turkey,
and Mexico deemed to be developing countries at a similar
stage of newly advanced economic development, on their way
to becoming developed countries and also known for their
significant influence on regional affairs. It was initially developed
as BRICS and since 2009, their governments have met annually at
formal summits. Russia hosted the most recent, 12th BRICS-TM
summit on 17 November 2020, virtually due to the COVID-19
pandemic (10–12). Therefore, the regulatory authorities of all
seven countries were invited to take part in the study.
The potential study participants were identified via each
respective authority’s general email addresses obtained from
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agency websites, LinkedIn, the research team’s personal contacts,
ex-employee, and local leading regulatory consultants for each
authority. They were selected based on their work experience
in the biologic or biosimilar division of the authority, having
held a position as a general manager or above or a leading
regulatory consultant with a close working relationship with
the relevant authority in the biosimilar space. They were sent
an electronic mail with brief information about project and
the questionnaire, the objective of the study, the number of
authorities to be included and requesting their agreement to
participate in the study.
Responses and conditions of acceptance were different across
all seven authorities. It took ∼18 months to receive agreement
from two agencies i.e., Agência Nacional de Vigilância Sanitária
(ANVISA), the Brazilian Health Regulatory Agency, Brazil,
and the South African Health Products Regulatory Agency
(SAHPRA). The respondents from the Central Drug Standards
Control Organisation (CDSCO), India agreed to participate
on anonymity and the Türkiye Ilaç ve Tibbi Cihaz Kurumu
(TITCK), Turkish Medicines and Medical Device Agency data
was gathered from public sources of the Agency such as Activity
report, official website, and Agency’s publicity manual. Two
agencies including the Russian MoH and Comisión Federal
para la Protección contra Riesgos Sanitarios (COFEPRIS), the
Federal Commission for the Protection Against Sanitary Risks,
Mexico did not respond to the letter of invitation. Consequently,
local senior regulatory consultants were engaged as proxy for
Russia andMexico. Despite tremendous efforts to establish direct
contact with the National Medical Products Administration
(NMPA) of China or via local Chinese regulatory consultants, the
outcome was unsuccessful.
On receipt of agreement to participate from the recruited
six countries, the self-administered Biosimilar Development,
Evaluation, and Authorisation (BDEA) questionnaire was sent
via email for completion by the respective authorities. This was
followed up by a face-to-face or virtual meetings after receipt
of the completed questionnaire. Such meetings were arranged
to understand and further interpret the respective agency’s view
and to verify the validity of the responses to the questionnaire.
In addition, copies of the relevant guidelines were requested as
part of the questionnaire to verify the responses and to correlate
the actual regulatory requirements. This phase of data collection
period took place between March and October 2020.
Measurement Tool
A semi-quantitative questionnaire, Biosimilar Development,
Evaluation, and Authorisation (BDEA) was developed (in
English) (Supplementary Material). This was based on slight
modification of the Centre for Innovation in Regulatory Science
(CIRS) questionnaire (13) and information from secondary
research in order to map the regulatory processes existing
within agencies (8). In addition, expert inputs were received,
and the initial drafts were prepared based on inputs from
Biologic and Radiopharmaceutical Drugs Directorate (BRDD)
– Health Canada, Turkish Medicines, and Medical Device
Agency (TITCK) and CIRS. Since the questionnaire was
initially developed for small molecules, the modifications were
introduced to make it biosimilar-specific. The BDEA was
further improved based on pilot validation performed by the
Regulatory Authority of Medicines, Equipment and Medical
Device (CECMED), Cuba.
Data Collection
Data for the comparator authorities was collected in 2019–2020.
The BDEA questionnaire which standardises the review process
allowing key milestones, activities and practises of the seven
regulatory authorities to be identified was completed by a senior
member of the biosimilar licencing division and validated by the
head of the division/authority. The final version of the BDEA
questionnaire dated March 2020, consists of 35 pages and the
questions are grouped under 22 categories and grouped into three
major sections as follows:
Part I - Organisation of the agency - This part of the BDEA
questionnaire consist of current agency structure, resources in
the biosimilar domain, and types of review models i.e., review
models employed for scientific assessment (Table 1), level of
data required, and extent of assessment of the data as well as
reliance on other authorities, if applicable.
Part II – Agency’s view on biosimilar development criteria
- This part covers questions pertaining to biosimilarity
principle, selection of RBP, comprehensive comparability
criteria including physico-chemical, non-clinical, and clinical
studies and “must submit” documents as part of a biosimilar
marketing authorisation application.
Part III – Marketing authorisation approval pathway - This
part presents questions with regards to key milestones i.e.,
the process of assessment starting from receipt of the
dossier, validation/screening, the number of cycles of scientific
assessments including the questions to the sponsor/applicant,
expert registration committee meetings to the final decision
on approval or refusal of a biosimilar for registration. A
standardised process map, developed based on the experience
of studying established and regulatory agencies of the
emerging economies, was embedded in the questionnaire.
Data Processing and Analysis
Data processing and analysis was carried out using Microsoft
excel; descriptive statistics was used for quantitative data and
content analysis was employed to generate themes and sub-
themes for qualitative data.
Ethics Approval
The study has been approved by the Health, Science, Engineering
and Technology ECDA, University of Hertfordshire [Reference
Protocol number: aLMS/PGR/UH/03332(1)].
RESULTS
For the purpose of clarity, the results will be presented in
three parts:
Part I – Organisation of agency;
Part II – Biosimilar development criteria; and
Part III – Marketing authorisation process.
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TABLE 1 | Models of regulatory review.
Type Title Definition
I Verification of Marketing
Authorisation Approval Application
• Importing agency “verifies” that the product intended for local sale has been duly registered as declared in the
application.
• Used to reduce duplication of efforts by agreeing that the importing country will allow certain products to be
marketed locally once they have been authorised by one or more reference agencies, elsewhere.
• Product characteristics and prescribing information for local marketing conforms to that agreed in the
reference authorisation.
II Abridged review of Marketing
Authorisation Approval Application
• Conserves resources by not re-assessing all scientific supporting data that has been reviewed and accepted by
reference agency but includes an “abridged” independent review of the product in terms of its use taking into
consideration local cultural and environmental factors.
• Includes a review of the biopharmaceutical (CMC) data in relation to climatic conditions and a benefit-risk
assessment in relation to use in the local ethnic population, medical practise/culture, and patterns of disease.
• Approval by a reference agency is a prerequisite before the local authorisation can be granted.
III Full review of Marketing
Authorisation Approval Application
• Suitable resources available including access to appropriate internal and external experts, to carry out a “full”
review and evaluation of the supporting scientific data (quality, non-clinical, clinical) for a major application.
CMC, Chemistry, Manufacturing, and Control.
Demographic Characteristics of the Study
Participants
Out of the seven regulatory agencies invited to take part in
the study, four agencies, ANVISA (Brazil), SAHPRA (South
Africa), CDSCO (India), and TITCK (Turkey) agreed to take part
and completed the questionnaire. Leading regulatory consultants
working closely with the agencies for biosimilar medicines from
Russia and Mexico also participated in the study. However,
multiple efforts to reach NMPA (China) either directly or
via regulatory experts were unsuccessful. The individuals who
completed the questionnaire held senior positions (general
manager or above) within the biologic divisions of their
regulatory authority. The regulatory consultants were Chief
Executive Officers (CEO) of their respective consulting firms.
Part I - Organisation of Agency
This provided information on agency size and the strength of
the biological division including the number of internal assessors
with their minimum qualifications and details on support
obtained from external assessors or committees (Table 2).
ANVISA - The capacity of the biological department is
around 1.6% in comparison with the total size of the agency.
The agency does not engage with external assessors, and the
applications are reviewed by qualified internal assessors all of
whom hold a PhD as their qualification. The agency relies on type
III data assessment (full review of the marketing authorisation
application) for most of the applications.
Russian MoH - There is no distinction between internal
assessors for the review of biological or non-biological marketing
authorisation applications, resulting in the same assessors
reviewing both types of applications. Product approval is based
solely on self-assessment by internal assessors applying type III
review model.
CDSCO - The capacity of the biological division within
CDSCO is 2% representing common internal assessors for
the review of all new biological and biosimilar applications.
The agency mandates a master’s degree in pharmacy as the
minimum qualification for internal assessors and takes expert
advice from external assessors for the review of both non-
clinical and clinical parts of the dossier. The agency has
several bodies with different responsibility including: Subject
Expert Committee (SEC) for clinical review which comprises
external physicians and regulators; the Review Committee for
Genetic Manipulation (RCGM) for non-clinical data; and the
Department of Biotechnology (DBT) for developing and defining
regulatory guidelines. The agency follows the type II (abridged)
review if the biosimilar has been approved by at least one
recognised reference agency and waives the non-clinical studies
if the product is already approved by more than one agency,
including China and South Korea subject to positive review
outcomes. The reference agencies defined for type II review
model are EMA, MHRA, USFDA, TGA, and BRDD. In addition,
the agency also carries out type III (full review) review but does
not mention verification review model.
SAHPRA - The overall size of the agency is around 200
personnel. There is a total of five reviewers for biological
applications with minimum qualification as shown in Table 2.
The agency outsources CMC, non-clinical and clinical data
evaluation to external evaluators and only allows a type III full
dossier review.
TITCK – The agency follows the type III review model and
takes advice from external assessors also for CMC, non-clinical
and clinical review.
COFEPRIS - The biological division represents 1% of the
overall size of the agency with a bachelor’s degree as the
minimum qualification for internal assessors. The agency relies
more on external experts under both the committees, the
SEPB (Sub-committee on evaluation of Biotech Products) and
the NMC (New Molecule Committee) headed by COFEPRIS.
The COFEPRIS is the only agency among these regulatory
agencies of the emerging economies following the type I
data assessment model relying on other reference agencies’
evaluation including the EMA, USFDA, and TGA. In addition,
the agency also conducts type III full dossier evaluation
for biosimilars.




















































Total agency staff 1,500 930 1,500 >200 1,172 2,000
Resource allocation in Biologic/Biosimilar division
Total staff 24 Not defined* 30 10 No information available 20
Number of reviewers 24 Not defined* 8 5 No information available 13
Capacity (%) 1.6 Not applicable 2 5 Not applicable 1
Internal assessors


















Support received No No information available Yes Yes Yes Yes
Area of expertise Not applicable Not applicable Non-clinical, Clinical CMC, Non-clinical, Clinical CMC, Non-clinical, Clinical CMC, Non-clinical, Clinical
Biosimilar advisory
committee






Type III Type III Type II, III Type III Type III Type I, III
Recognised
reference agencies
Not specified Not specified EMA, USFDA, BRDD,
MHRA, TGA
Not specified Not specified EMA, USFDA, TGA
*No separate biologic division; #RCGM and SEC committee details excluded; CMC, Chemistry, Manufacturing and Control; SEC, Subject Expert Committee; RCGM, Review Committee on Genetic Manipulation; DBT, Department of
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It is evident from Table 2 that SAHPRA, TITCK, CDSCO,
and COFEPRIS agencies use the support of external assessors
for review of application despite having an internal biologic
division. This reflects a shortage of resources related to internal
biologic reviewers. In addition, allocation of common assessors
for biologic and non-biologic applications such as that practised
by the Russian MoH may lead to suboptimal subject matter
expertise. All the agencies follow “type III - Full review of the
marketing authorisation application” data assessment model.
In addition, CDSCO follows “type II - Abridged review” and
COFEPRIS follows “type I – Verification review of marketing
authorisation application.” This indicates that the reliance of
these regulatory agencies of emerging economies on type I and
type II models is less prevalent.
Part II - Biosimilar Development Criteria
Establishing biosimilarity to the reference biologic product
revolves around several steps starting from in vitro analytical
testing and quality characterisation, non-clinical comparative
pharmacology testing to toxicology, PK/PD studies, and clinical
trials (clinical safety and efficacy) (14). Although it is evident,
that the regulatory standards of these six emerging economies
are mostly aligned and largely modelled on WHO guidelines
(8), there is a lack of homogeneity in dossier requirements
across these agencies posing a challenge to global development
programmes. Such differences as presented by the regulatory
agencies have been analysed and presented here.
Biosimilarity
All the six regulatory agencies of these emerging economies
expect the sponsor to demonstrate biosimilarity of the
proposed biosimilar product with the reference product. This
includes proving satisfactory physicochemical and biological
characterisation with in vitro non-clinical PK/PD studies and
literature based clinical performance evaluation, additional in
vivo safety data plus confirmatory clinical safety and efficacy
trial. However, expectations for local or global clinical studies
vary among the agencies. The ANVISA, SAHPRA, TITCK
accept clinical studies performed in any country globally, while
CDSCO and COFEPRIS mandate a local study. The Russian
MoH accepts global studies as long as a trial includes Russian
patients. In addition, extrapolation of indications is allowed
subject to fulfilment of conditions defined by each agency.
Furthermore, these regulatory agencies of the emerging
economies (except Russian MoH and TITCK) do not regulate
interchangeability by law and allow a prescriber to decide
based on a patient’s need. However, in Russia, biosimilar
products can be interchangeable with the reference product
by law whereas in Turkey, the reimbursement institution
authorises interchangeability.
Comparative Quality Characterisation
Reference Biologic Product (RBP) Selection
Selection Criteria. In response to questions on the RBP selection,
the agencies mostly indicatedmandatory requirements for locally
authorised reference product (based on a full dossier submission
including quality, safety, and efficacy) for comparability studies
(Table 3).
Primary and Alternate Source of RBP. Flexibility in terms of
sourcing the RBP from other ICH/reference countries exists in
CDSCO, TITCK, and COFEPRIS, in the event of non–availability
of locally authorised reference products. In addition, TITCK
also accommodates use of a non-locally authorised RBP as well
as locally sourced reference products for certain clinical safety
studies (PK/PD study in human), non-clinical studies (in vivo),
and development studies such as “quality target product profile”
(QTPP) which is a summary of the quality characteristics of the
respective biosimilar. These quality characteristics are essential
to ensure that the finished product meets the required standard
of quality.
Use of RBP Authorised in Emerging Countries. None of the
agencies accept authorised reference products from other
emerging countries, except CDSCO which may then only
consider this in emergency situations such as the COVID-
19 pandemic.
Criteria of RBP Batches. Unlike the Russian MoH and
COFEPRIS, the regulatory agencies of Brazil, India, South
Africa, and Turkey also mandate the use of multiple batches
of RBP with varied expiry dates. However, ANVISA, has
provisions for the changeover of RBP during development and
comparability studies.
Bridging Study Requirement. All the six regulatory agencies of
BRICS-TM has not specified the bridging study requirements.
Data Sharing Arrangements. ANVISA established data sharing
arrangements with advanced regulatory agencies such as EMA,
USFDA, PMDA, and MHRA. CDSCO also holds a data sharing
agreement with EMA and USFDA. In contrast, COFEPRIS
does not have a data sharing arrangement with other advanced
regulatory agencies and expects a full dossier submission
for products approved by a foreign agency (Table 3). Such
arrangements of sharing of information about the product among
the regulatory agencies would help the agency to understand if
the RBP batch used for the development process has been made
in the same facility or same process or same cell line and if
the same information has been submitted to both the agencies.
With evaluation of such shared data, the agency can waive the
additional requirements on the RBP required for submission or
waive the bridging studies. This type of data-sharing agreements
would greatly decrease costs of biosimilar development.
The varied expectations for RBP sourcing from these agencies
demonstrate the challenge in procuring multiple lots of RBP
and the non-convergence in regulatory requirements, thereby
limiting the opportunity for multi-country development.
Analytical Specification and Method
The similarity of physicochemical and biological properties of
biosimilar and reference product is demonstrated using two or
more orthogonal analytical methods (3). In keeping with this, the
current assessment underlines the need for orthogonal methods







































TABLE 3 | RBP selection criteria for six regulatory agencies of BRICS-TM.
Regulatory agency Selection criteria Primary source of RBP Alternate source of
RBP
Use of RBP authorised
in emerging countries





ANVISA Approved based on full
registration dossier with
ANVISA
Locally authorised RBP First innovator or
biosimilar product
authorised locally
Not accepted Multiple batches of RBP
with varied expiry dates
Not specified EMA, USFDA, PMDA,
MHRA
Russian MoH Approved based on full
registration dossier with
Russian Federation
Locally authorised RBP First innovator product
authorised locally
Not accepted Singe batch of RBP Not specified Not specified
CDSCO Approved based on full
registration dossier with
CDSCO
Locally authorised RBP ICH countries Not accepted Multiple batches
(minimum 3 batches) of
RBP with varied expiry
dates
Not specified EMA, USFDA
SAHPRA Approved based on full
registration dossier with
SAHPRA
Locally authorised RBP First innovator product
authorised locally
Not accepted Multiple batches of RBP
with varied expiry dates
(draft stage; but followed
in practise)
Not specified Not specified
TITCK* Approved based on full
registration dossier with
TITCK
Globally authorised RBP EMA, USFDA, BRDD,
TGA, PMDA, MHRA,
BfArM
Not accepted Multiple batches of RBP
with varied expiry dates
(draft stage; but followed
in practise)
Not specified Not specified
COFEPRIS Approved based on full
registration dossier with
COFEPRIS
Locally authorised RBP EMA, USFDA, TGA,
PMDA
Not accepted Minimum 3 batches Not specified No data sharing
arrangement and expects
full dossier
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for purity, impurity and contaminants characterisation as
indicated by the responses from all the six emerging economies.
Furthermore, as specified clearly in WHO SBP guidelines
(15), specifications for a SBP (Similar Biotherapeutic Product)
will not be the same as for the RBP due to the difference in
manufacturing process and analytical procedures followed by
the manufacturer. Hence, specifications should be set based on
the manufacturer’s experience with the SBP (e.g., manufacturing
history; assay capability; safety and efficacy profile of the
product) and the experimental results obtained by testing and
comparing the SBP and RBP. However, the regulatory agencies
of these emerging economies’ consideration for determining
specifications and analytical methods for proposed biosimilar
product varies across agencies.
The ANVISA and TITCK prefer analysis of multiple RBP
lots with varied age along with the SBP. The COFEPRIS
requires minimum of three batches of RBP. The Russian MoH
predominantly expects specifications to be designed exactly the
same as the RBP whereas CDSCO, SAHPRA, and COFEPRIS
define specifications based on manufacturer’s experience of the
SBP and RBP, consistent with WHO guidelines.
Comparative Stability Studies
Four of the six regulatory agencies of these emerging economies
(i.e., Brazil, Russia, South Africa, Mexico) indicated the need
for comparative accelerated and stress stability studies, along
with real time, real condition stability studies conducted in their
respective climatic zone to support the shelf-life. CDSCO (India)
does not require comparative studies and TITCK (Turkey)
considers it only as supportive data for biosimilar development.
Comparative stability data is essential for “totality-of-
evidence” to determine biosimilarity (16) and is an integral
part of any biosimilarity assessment (17). As was evident from
the responses, all the six regulatory agencies of these emerging
economies are aligned with global standards in this aspect.
However, CDSCO in practise, may consider an application even
in the absence of side-by-side accelerated and stress stability
studies though mandated as per the Guidance on Similar
Biologics (18).
Non-clinical Studies
The six regulatory agencies of the emerging economies state that
in vitro comparative functional assays such as biological assays,
binding assays, and enzyme kinetics; in vivo pharmacokinetics,
pharmacodynamics and immunogenicity studies; and in vivo
comparative repeat dose toxicity studies are requisite for
non-clinical studies. In addition, local tolerance studies and
other toxicological studies are expected by CDSCO, TITCK,
and COFEPRIS. Safety pharmacology studies are required by
SAHPRA. In TITCK, the evaluation and acceptability are on
case-by-case basis.
For in vivo studies, the Russian MoH advises the use of
transgenic animal/ transplant models in a GLP setting while
CDSCO suggests toxicity studies in rodent and non-rodent
animals for proving statistical difference and advises to submit
scientific justification for the choice of animal model. If a relevant
non-rodent model is not available in India, then non-rodent
studies can be waived by the Review Committee on Genetic
manipulation (RCGM). The TITCK reported that the evaluation
and acceptability of non-clinical studies is solely on a case-by-
case basis in alignment with EU and ICH guidelines (19, 20).
The rest of the six emerging agencies’ responses were incomplete
regarding the type and minimum sample size of each species for
the study.
Clinical Studies
Table 4 presents the clinical trial requirements for biosimilar
development in the six emerging economies.
Applicants need to submit PK/PD and clinical safety and
efficacy studies data as part of a biosimilar application in all the
six regulatory agencies of these emerging economies.
PK/PD
The PK/PD requirement in terms of design, endpoints,
fingerprinting approach, and combining PK and PD studies are
uniform across these emerging economies, closely aligned with
the standards set by the EMA (20).
Immunogenicity
The responses from the agencies indicate the need for
comparative immunogenicity as part of a biosimilar application,
except for the Russian MoH. The CDSCO accepts that
immunogenicity data can be obtained either from PK/PD
or Phase III efficacy studies. Furthermore, all the agencies
considered the extrapolation of immunogenicity studies to other
indications, subject to the approved indications of the RBP.
The expectations for such studies are defined in the Biosimilar
Guidance 2016 in the case of CDSCO (18), however such clarity
is yet to be defined by the other regulatory agencies of these
emerging economies.
Comparative Clinical Efficacy Studies
Clinical Study Design. In general, all the regulatory agencies
of these emerging economies studied expect a randomised,
parallel group, double-blind, adequately powered clinical study
using efficacy endpoints. Furthermore, ANVISA and COFEPRIS
consent to both non-inferiority and equivalence design for
clinical studies. The Russian MoH prefers an equivalence design,
while CDSCO accept a non-inferiority design. In addition,
the Russian MoH and CDSCO expect clinical comparability
studies in paediatric and elderly populations in cases of
extrapolated indications.
Local Clinical Studies. The ANVISA does not mandate
performance of a local clinical study. However, for a global
study, the agency mandates advice on regulatory expectations
for clinical studies prior to protocol development, which is
legally binding. Further, the foreign patient data is accepted
by the agency as part of the biosimilar application if there are
no foreseen genetic differences between the population studies
and Brazilians. The TITCK has a similar requirement to that of
ANVISA for acceptance of foreign patient data.
The Russian MoH requires local clinical studies for Phase
III and mandates the inclusion of Russian patients when using
global studies. Similarly, CDSCO requires local Phase III clinical
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trials in India. The sample size defined by CDSCO is a minimum
of 100 patients in each arm. Usually, non-legally binding pre-
submission advice is provided by the agency before the start of
clinical trials. The agency does not accept foreign patient data as
part of a biosimilar application.
As for COFEPRIS, the local clinical study requirement
depends on the demonstration of comparability at CMC
and non-clinical stages, as well as the robustness of the
already performed clinical studies. The agency is open for
inclusion of foreign patients in clinical efficacy studies for
proving biosimilarity.
Part III - Marketing Authorisation Approval
Pathway
The biosimilar application approval process includes the
following steps: scientific advice, clinical trial application (CTA)
approval process; and dossier review process including validation
of application, queuing, scientific assessment, sample analysis,
GMP certification, and product approval (Figure 1).
Scientific Advice
Throughout the development process of biosimilars, developers
need the respective agency’s advice. This can include;
reference product selection and overall development strategy;
evaluation and discussion post physicochemical and biological
characterisation with in vitro non-clinical data; in vivo clinical
data and justification of differences and clinical safety and
efficacy trial protocol design and approval; and overall dossier
content. The advanced agencies such as the USFDA (21) and
the EMA (22) offer biosimilar developers formal meetings for
scientific advice to perform appropriate tests and studies, so that
no major objections regarding the design of the tests are likely
to be raised during the review of the marketing authorisation
application. This approach supports the timely and sound
development of high-quality, effective and safe medicines for the
benefit of patients and also helps to avoid patient studies that will
not produce useful evidence.
Three of the six agencies (i.e., ANVISA, CDSCO, and
SAHPRA) offer pre-submission advice for the biosimilar
developers. The advice from ANVISA can be obtained
through face-to-face meetings, electronic mails, or written
correspondence whereas CDSCO and SAHPRA prefer face-to-
face meetings. The expert advice received through such meetings
is not legally binding on both parties, however, agencies do
expect compliance to their comments during development of the
biosimilar. The Russian MoH, TITCK, and COFEPRIS are yet to
establish any formal meeting procedures.
The absence of scientific advisory meetings in TITCK has also
been highlighted in an earlier study (23) where the importance
of such interaction with agency has been emphasised. In Russia,
face-to-face interaction between the government and a biosimilar
manufacturer is not allowed and all regulatory communications
must be carried out in writing (24).
Clinical Trial Application (CTA) Approval Process
The CTA is evaluated and approved by specific committees
designated by the agencies such as: Coordenação de Pesquisa
Clínica (ANVISA); Subject Expert Committee (CDSCO); and
Clinical Trials Committee (SAHPRA). The Russian MoH and
TITCK assign internal assessors to review the application. No
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FIGURE 1 | Marketing authorisation approval milestones.
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TABLE 5 | Timelines for biosimilar review and approval process.
ANVISA Russian MoH CDSCO SAHPRA TITCK COFEPRIS
CTA review 90 days 45 days 90 days <70 days* 30 days 45 days
Validation Not applicable 5–15 days No specific step 15 days 30 days No information available
Queuing 60–180 days No information available 14–56 days <28 days 60–180 days 180–365 days
Scientific Committee review 30 days 30–90 days No information available 60 days No information available 90 days
Decision via committee meeting Not applicable 30 days Not applicable ≤240 days# Not applicable 90 days
Issuance of Marketing Authorisation <30 days <30 days 90 days <30 days <30 days 90–180 days
*There are cases where this turnaround time might be prolonged i.e., an unfamiliar investigational product which may be referred to external reviewers or other committees of SAHPRA
for input for new applications.
#Registration within 240 days, may be earlier.
ANVISA, Russian MoH, SAHPRA, TITCK follows calendar days; CDSCO and COFEPRIS follows working days.
clarity on this topic was received from COFEPRIS. An integral
part of the CTA is the Ethics Committee (EC) approval letter,
which is to be obtained from the Institutional Review Board of
hospitals or institutions where the clinical trial is intended to
be performed. The Russian MoH and COFEPRIS require an EC
letter as part of the initial application, whereas the rest of the
agencies are flexible and will accept such letter during the review
process or post approval of the CTA.
All the regulatory agencies have varied timelines for CTA
approval as shown in Table 5.
Dossier Review and Approval Process
Dossier Content
The six regulatory agencies of the emerging economies
accept electronic CTD dossiers as the format for marketing
authorisation applications (MAA) for biosimilar products.
The Certificate of Pharmaceutical Product (CPP) is a
mandatory document as part of the initial dossier by
the Russian MoH and CDSCO, for acceptance of the
application by the agency. The ANVISA, COFEPRIS,
and TITCK provide relaxation for the CPP submission
before granting a marketing authorisation. In addition,
TITCK also accepts any marketing authorisation certificate
and published approvals from the relevant agencies’
official websites.
Post submission by the sponsor, the product dossier passes
through different stages such as screening against a checklist,
acceptance for further review, queuing for review and scientific
assessment resulting in approval or non-approval of the
application by the agency.
Screening and Validation
As part of the screening or validation process, all the agencies
verify applications against a standard checklist and request
additional data (except CDSCO) if some documents are
missing. In case of CDSCO, submission will not be uploaded
on the SUGAM online portal if the dossier is inadequate.
Further, all the information pertaining to “milestone” dates
are recorded during the review process into an electronic
tracking/recording system maintained by the agencies, i.e.,
DATAVISA (ANVISA), GRLS (Russian MoH), SUGAM
(CDSCO). In case of SAHPRA and COFEPRIS, there is no
specific system in place, whereas no information available from
TITCK on the same.
Queuing
The queue time for dossiers awaiting review ranges from 4 weeks
to 1 year as displayed in Table 5. All agencies, except the Russian
MoH and COFEPRIS, confirmed that priority products including
biosimilars are not required to be in a queue for review.
Scientific Assessment
Scientific assessment of biosimilar applications depends on
the outcomes of the dossier review, sample analysis, and
GMP certification.
For dossier review, CDSCO and SAHPRA use external
assessors, however, there is no contractual agreement defining the
timelines for review of the technical data. ANVISA and TITCK
issue an emergency letter to sponsors in the case of a sudden
unforeseen crisis as and when they review different sections of
the dossier, while the rest of the agencies collate quality, safety,
and efficacy deficiencies in one batch and send it to the applicant.
The obligatory time for developers to respond to queries varies
between 3 and 6months and referred to as “clock stop.” Failure to
meet the stipulated time, leads to rejection of the application with
forfeiting of the fees with ANVISA, the Russia MoH, CDSCO,
and COFEPRIS. The TITCK sends official letters for rejection to
the sponsor, but the company can object to the same; however,
there is no predetermined deadline in this aspect, while SAHPRA
allows for extensions. Further, in case of a negative opinion from
the scientific committee, CDSCO has provisions for sponsors
to approach the technical committee and apex committee for
their intervention and decision. The Russian MoH and ANVISA
have no such additional provision and also there was no clarity
received in this regard from COFEPRIS. The defined target
timeline for scientific review by each of the regulatory agencies
also varies as detailed in Table 5.
Sample Analysis. Most of the regulatory agencies of these
emerging economies expressed a requirement of sample analysis
at specified approved quality control laboratories as part of
the dossier approval process. The ANVISA and SAHPRA
rely only on technical documentation for biosimilar products
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and do not require sample analysis. The Russian MoH,
TITCK, and CDSCO expect sponsors to submit samples along
with analytical specifications and methods, reference/working
standard and analytical columns. The CDSCO additionally
require an analytical validation package. The maximum time to
analyse samples is 110 calendar days as defined by FGBU (Russia)
while no such deadlines are specified by other agencies.
GMP Inspection. These six regulatory agencies of emerging
economies also mandate on-site GMP inspections for biological
substances and biosimilar product manufacturing sites.
Generally, each agency (except CDSCO) performs inspection
during the dossier evaluation process, whereas CDSCO inspects
site/s after completion of the dossier assessment. For TITCK,
separate site GMP application is required, and the agency
conducts inspection before scientific assessment of dossier,
unless there are priority products. Also, CDSCO and SAHPRA
accept GMP certification from reference agencies i.e., EMA (EU),
BRDD (Canada), MHRA (UK), USFDA (USA) instead of on-site
inspections. In addition, CDSCO accepts TGA (Australia)
certification whereas COFEPRIS accepts EMA (EU), TGA
(Australia), and USFDA (USA) certification. The TITCK does
not accept foreign agencies’ GMP inspections.
Across these emerging economies, the final decision maker on
the marketing authorisation is the head of the agency.
Public Assessment Reports (PARs) and Approval Metrics
Except for ANVISA, the regulatory agencies of these emerging
economies are yet to establish procedures for the issuance of
a public assessment report or clarifying the basis for approval
for the product. In such scenarios, measuring real approval
timelines for biosimilars becomes arduous. The biosimilar
approval metrics for the duration of 2017–2019 for ANVISA is
presented in Figure 2.
DISCUSSION
Biosimilar products are complex molecules produced using
highly complex manufacturing processes. Due to the complexity
of the biosimilar products, regulatory requirements for analytical
comparability, non-clinical, and clinical studies vary with the
geographies (25), particularly in emerging economies like BRICS-
TM, as evident from the secondary research (8). Furthermore,
with multiple prospective manufacturers on the horizon,
the need arises for a streamlined regulatory guideline in
emerging economies that ensure biosimilarity, comparability,
and interchangeability with respect to safety and efficacy of
the product (25). Although substantial progress has been
made in regulatory frameworks for chemical drugs, progress
is less robust in developing countries, and implementing
regulatory frameworks for biologic medicines, particularly
biosimilar medicines (26). The recent studies reported in the
literature suggest that the regulatory challenges in biosimilar
space continue to be a topic of interest and deserves
further debate. However, our study, in comparison to existing
knowledge in the area, provides insight about TITCK (Turkey)
and COFEPRIS (Mexico) agencies pertaining to biosimilar
development challenges, in addition to the 20 countries included
in the WHO survey reported by Kang et al. (27). The
findings reposted by Garcia et al. (28) of Latin America
are complemented by this study for challenges pertaining to
biosimilar approval pathway. Furthermore, Sharma et al. (29)
discuss global regulatory requirements on biosimilars and their
difference amongst generics based on ophthalmic perspective
while Cohen AD et al. (30) focuses on clinical practises specific
for the treatment of psoriasis. However, our study reported
here provides insight about biosimilar regulations irrespective of
therapeutic areas.
Regarding the type of dossier assessment and allocation of
resources for the dossier evaluation by the regulatory agencies,
external evaluators are involved for review of applications by
SAHPRA, TITCK, CDSCO, and COFEPRIS, while Russian MoH
has common assessors for biologic and non-biologic applications.
All the six emerging agencies follow “Type III - Full review
of the marketing authorisation application” data assessment
model. In addition, CDSCO follows “Type II - Abridged
review” and COFEPRIS follows “Type I – Verification of
marketing authorisation application”, with a clear indication of
less prevalence of Type I and Type II review models among these
countries. It has been commonly cited that building capacity and
expertise in a national regulatory authority is a long-term process
and quick resolutions lie in relying on information from other
regulatory authorities or a shared or abridged review models
(31). The study results reveal non-transparency and limited co-
operation amongst the agencies for biosimilar medicinal product
regulatory review. The outcome of this study may benefit these
agencies by highlighting need for adopting shared review or
reliance review models for scientific assessment of biosimilar
applications. Evidence of shared review by SAHPRA (South
Africa) with the national regulatory authorities of the member
countries of the ZaZiBoNa work sharing initiative (32) such as
Zambia, Zimbabwe, Botswana, Namibia offers an opportunity
for an efficient and effective regulatory process for biosimilar
evaluation in countries with limited resources. Brazil and Mexico
are part of the PAHO (33) region, and Mexico uses the reliance
model with authorities of regional reference, which includes the
USA and Canada, thus using Type I review model for scientific
assessment depending on the product. However, ANVISA, Brazil
do not recognise any reference agencies for the dossier review
and carry out full review (Type III). Although Brazil and Mexico
are recognised as regional reference agencies in the America, the
products authorised in these countries are neither recognised
nor the data relied upon by other emerging economies within
these regions.
The common expectations on demonstration of biosimilarity
to the RBP across these emerging agencies includes satisfactory
physicochemical and biological characterisation, in vitro non-
clinical studies, additional in vivo safety data along with
confirmatory clinical safety and efficacy data. While ANVISA,
SAHPRA, TITCK accept global clinical studies, Russia MoH,
CDSCO, and COFEPRIS mandates conduct of clinical efficacy
trials in the local population. The non-acceptance of global
clinical data and repetition of clinical studies mandatorily in
local population by these regulatory agencies adds to unnecessary
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FIGURE 2 | Biosimilar approval metrics of ANVISA – 2017–2019.
development costs (34). Such duplication of studies further is
likely to impact the overall biosimilar development process and
approval timelines in these countries (27).
With regards to the selection criteria for RBP and its
procurement, these emerging agencies mandated locally
authorised reference product (based on a full dossier including
quality, safety, and efficacy) for comparability studies. While
few agencies like CDSCO, TITCK, and COFEPRIS provide
flexibilities for sourcing RBP from ICH/ reference countries,
ANVISA, Russian MoH, and SAHPRA have stringent regulation
on using only the locally licenced RBP. In Russia, a comparator
product cannot be sourced from another regulatory jurisdiction
since it is only allowed to use a reference comparator drug that
has Russian marketing authorisation (35). Further, although
most agencies expect multiple batches of RBP with varied
expiry dates, the exact number of RBP batches required for
comparability studies was not clearly defined by the agencies.
Also, reference products authorised by other emerging countries
are not accepted by these agencies, excepting in emergency
situations, in case of CDSCO. There is seemingly a non-
convergence in the regulatory requirements among these
agencies with regards to RBP selection criteria. Acceptance of a
non-locally licenced/sourced RBP by few countries and others
that require a locally licenced reference product without any
leverages, also demonstrates the challenge in procuring multiple
lots of RBP, thereby posing a potential barrier for the biosimilar
development process in these countries. It has been suggested
by WHO, that exchange of information with other national
regulatory authorities by accepting sourcing of non-locally
licenced reference products, and avoiding unnecessary bridge
studies (31) can circumvent such challenges in RBP sourcing.
In general, in vitro comparative functional assays are
required by all the six emerging agencies along with in
vivo pharmacokinetics, pharmacodynamics and immunogenicity
studies. There is a mandatory requirement for in vivo repeat dose
toxicity studies from all the countries; with TITCK evaluation in
accordance with EU and ICH guidelines, on a case-by-case basis.
Further, CDSCO expects non-clinical studies in rodent and non-
rodent animal and Russian MoH in transgenic animal/transplant
models to be conducted. However, there is no clarity on the
type of study or species or other requirements from other
agencies. The study clearly shows the lack of consistency in
the regulations on non-clinical aspects from these countries.
Also, such mandatory requirements for non-clinical studies
demonstrates a lack of scientific approach toward the assessment
of data indicating lack of full implementation of a “step-wise
approach” for proving biosimilarity (36).
These six regulatory agencies of the emerging economies
mandate PK/PD studies (regulations being similar to EMA),
clinical safety and efficacy studies along with comparative
immunogenicity data as part of a biosimilar application.
However, the Russian MoH does not provide clarity on
expectations on immunogenicity studies nor for extrapolation of
immunogenicity data to other indications inmost of the agencies.
Further, as discussed earlier, the acceptance of clinical efficacy
data from foreign patient data is not supported by all the agencies.
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Such a mandate on confirmatory clinical efficacy studies shows
the agencies lack in science-based approach for review of dossier.
It is apparent that the understanding by these agencies on the
importance of comprehensive analytical comparability studies
and the evaluation of comparability data for any structural and
functional differences is inadequate. Further, non-recognition
and non-acceptance of global data leading to duplication of
studies, impacts on development costs and delays in approval
of the biosimilar product (37). Emphasis on recognising data
from other reference countries and the relevance of advanced
analytical science to prove comparability in place of confirmatory
clinical data has also been focussed by IGBA in their policy
paper (36).
Scientific advice helps to ensure that developers perform
the appropriate tests and studies, so that no major objections
regarding the design of the tests are likely to be raised during
the evaluation of the marketing authorisation application. This
also helps avoid patients taking part in studies that will
not produce useful evidence. Such pre-submission advice for
biosimilar developers to get agencies’ opinions on the biosimilar
development process is only offered by a few of these emerging
agencies like ANVISA, CDSCO, and SAHPRA. These advisory
meetings are through face-to-face meetings, electronic mail or
written responses. However, there are no set procedures for
any formal meeting in the rest of these emerging agencies. The
absence of a communication channel between the biosimilar
developer and the national health authority greatly impacts
the overall development process. With an increasing number
of biosimilar developers across the globe, the scientific advice
requests to developed agencies like EMA is expanding. EMA has
also launched a pilot project in 2017 (38) for “tailored scientific
advice” for the development path for biosimilar medicines, to test
the added value and feasibility of the project. Implementation of
scientific advisory meetings by these six regulatory agencies of
emerging economies, similar to those by established regulatory
authorities would support the potential manufacturers to have
better clarity on the regional regulations and incorporate them
in their global biosimilar development program.
The dossier content requirements for biosimilar Marketing
Authorisation Application (MAA) are similar within these
regulatory agencies of emerging economies. All these agencies
accept electronic CTD and mandate CPP as part of the dossier,
however the flexibility over time of the submission of such
administrative documents (initial dossier or post approval of
dossier) varies. Relaxation in terms of provision of other
published approvals and authorisation documents in lieu of CPP
by few agencies, exists. The dossier screening and validation
process against a standard checklist is uniform across all the
six emerging agencies, however the acceptance of the MAA
with insufficient data differs with the agencies. The queueing
time for dossier review varies from 4 weeks to 1 year, with
almost all the agencies discounting the priority products (except
the Russian MoH and COFEPRIS). The biosimilar application
is considered for scientific assessment based on the outcome
of the dossier review, sample analysis, and GMP certification.
Although most of the agencies evaluate the dossier internally,
a few opt for external evaluators for dossier evaluation. This is
partly due to the full review of dossier (Type III data assessment
model) by the agencies. Joint or shared review of the dossiers
will ease the resource constraint or the dossier review process
among these agencies (27). Further, such joint review can have
a positive impact on the query response timelines, by allowing
the sponsors to address the deficiencies in a single window rather
than responding to the same query multiple times to different
agencies. Such provisions might further minimise the number
of dossier rejections within the agency, thereby allowing more
biosimilars to penetrate into these emerging markets.
Despite the technical dossier, the requirement for samples
by all these emerging agencies (except ANVISA and SAHPRA)
along with reference standard/working standards for testing at
qualified laboratories for the biosimilar approval process extends
the overall biosimilar approval timelines. Additionally, each of
these agencies mandate on-site GMP inspections for biological
substances and biosimilar product manufacturing sites. Though
inspection of the manufacturing site is essential for ensuring
compliance to global manufacturing standards and assuring the
quality of the product, individual or separate inspections by each
of the emerging agencies leads to duplication. Instead, acceptance
of reference agency GMP certification (including EU, PIC/S), as
permitted by CDSCO, SAHPRA, and COFEPRIS will improve
the process efficiency of the agencies (39). Also, collaboration,
reliance or joint inspections among these regulatory agencies
will minimise the resources and efforts required by developers,
resulting in increased regulatory performance (39–41).
Based on the evaluation of the study results, following key
outcomes from this study can be considered for an effective
biosimilar development and approval process among these
emerging agencies -
• This study emphasises the need to foster effective collaboration
between regulators and developers in six emerging agencies in
order to streamline the development strategies and approval
pathways for biosimilar products.
• A formal approach to regular, appropriate, and tailored
scientific advice from regulatory agencies to developers will
help to align expectations on both sides and support step-
by-step development, thereby reducing the need for certain
studies i.e., in vivo non-clinical studies. This may also help to
shorten the overall review and approval timeline.
• Significant challenges in sourcing RBP for comparative
studies necessitates regulatory flexibility in norms for
sourcing the comparator. Allowing RBP from other emerging
countries will also facilitate the use of common biosimilar
development programs.
• While appropriate resource allocation and upskilling of
regulators needs to be considered, adoption of an alternative
regulatory framework such as abridged review models might
help in optimising the use of resources within the biosimilar
departments of these six emerging agencies.
The biosimilar therapy in emerging economies is still in
the infancy stage with little or no presence but expected
to show strong growth (4) remains scope for improving
transparency in the national regulatory frameworks and aligning
regulatory standards among the emerging economies. In the
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light of the current global regulatory environment and the
pandemic challenges, it was prudent for both regional and
national regulatory authorities (NRAs) to re-evaluate regulatory
requirement for development and approval of biosimilars taking
into account the challenges faced by different stakeholders.
Although there were no remarkable changes in biosimilar
guidelines in the six emerging economies between 2018 and 2020,
there have been progress toward relaxing few guidelines with
regards to conduct of clinical trials and GMP inspections. For
instance, ANVISA, Brazil, has introduced certain relaxation of
clinical trial procedure and allowed sponsors to modify or amend
protocol without ANVISA’s authorisation. In addition, if clinical
study is related to COVID-19 then clinical trial consent can be
obtained immediately upon formal submission of the protocol.
As per the resolution of the Collegiate Board of ANVISA, RDC
no 346/2020 of March 13th, ANVISA has adopted an alternative
route for GMP certification of Active Pharmaceutical Ingredient
(API), drugs and health products, based on remote inspection
or reliance from other health authorities. If the manufacturer is
accredited by PIC/s GMP certification, then ANVISA can process
a faster GMP certification (42). RDC no 348/2020 of March
17th allows flexibility in evidence and prioritisation in analysis
if the product has the therapeutic indication for treatment or
prevention of the pandemic disease (43). Similarly, the Russian
agency has taken step to have remote GMP inspections for
foreign manufacturers (44).
The CDSCO has upgraded regulatory standards for clinical
trials via the New Drug Clinical Trials Rule 2019 (45). In India,
Schedule Y of Drugs and Cosmetics Act and Rules defined the
requirement for clinical trials of new drugs and investigational
new drugs for manufacturing and import prior to the New
Drug Clinical Trial Rules (45) came into effect. The revised
comprehensive NDCTR closes some of the gaps existing in
Schedule Y in terms of number of subjects, nature and timing
of non-clinical studies, content of the proposed protocol for
performing clinical trials. As part of the first schedule, General
Principles and Practises for Clinical Trial section (3) (2)(c) (iii),
pertaining to new drugs approved outside India, the phase III
study may need to be performed in India. It explicitly states
that Phase III studies need to be carried out if scientifically
and ethically justified to establish data for safety and efficacy of
drugs in Indian patients. It further states that PK studies may
be required by the Central Licencing Authority (CLA) in Indian
patients. The CDSCO, India, has also developed rapid response
framework for COVID-19 vaccines. Accordingly, the agency is
open to considering pre-clinical or clinical data generated outside
the country and shorten development requirements to reduce
the time for approval (46). In addition, WHO GMP/ Certificate
of Pharmaceutical Product (CoPP) extension of an additional
6 months has been provided and special permission has been
granted to import drugs with <60% of remaining shelf life, up to
October 2020. Similarly, the SAHPRA, South Africa, has issued
policy documents for conducting clinical trials, based on the
FDA’s guidance on conduct of clinical trials of medicinal product
during the COVID-19 pandemic (47).
Furthermore, The TITCK, Turkey, announced some flexibility
due to COVID-19 such as postponing marketing authorisation
certificate’s annotation process, online stakeholder meetings
regarding marketing authorisation activities, accepting CPP or
similar certificate without apostille, readability test waiving until
end of 2021, extension of GMP validity period to end of
2021 (48).
LIMITATIONS OF THE STUDY
The study presented covers evaluation of responses obtained
from 6 out of 7 (85.7%) regulatory agencies. While ANVISA,
Russia MoH, CDSCO, SAHPRA, TITCK, and COFEPRIS
responses were obtained, the multiple efforts to reach
NMPA (China) either directly or via regulatory experts were
unsuccessful. Though the non-participation of China in this
study could be considered as a limitation, however the survey
(even without China) encompasses a large, diverse and important
segment of the world population and pharmaceutical market, so
it should provide strategic information to pharma companies, as
well as national regulatory authorities and international bodies.
The response pertaining to biosimilar approval metrics i.e.,
applications received, applications screened and accepted for
further review, biosimilars approved, biosimilars refused and
average approval times was received only from ANVISA. The
response from other agencies would have helped understand the
process efficiency and provided benchmark in terms of basis of
approval to biopharmaceutical companies.
CONCLUSION
To conclude, many medical treatments and medicines now lay in
Biotechnology, where understanding of the patient’s physiology
and cell make up is the key to treatment. Biological drugs
bring that value in the treatment of many disabling and life-
threatening chronic diseases, including inflammatory arthritis,
certain types of cancer, diabetes, inflammatory bowel disease,
Crohn’s disease, psoriasis, and COVID-19. Biosimilars can help
the public gain access to health through affordability, and that
is where the need for the regulatory guidelines of biosimilars
can contribute through harmonisation and simplification. The
research undertaken presents an effort in that direction. This
study has, for the first time, evaluated the regulatory requirement
for approval and development of biosimilars in these six
emerging economies and has identified a lack of alignment in
certain areas that would benefit from standardisation. There
remains scope for improving transparency in the national
regulatory frameworks and aligning regulatory standards among
these emerging economies. This would impact the overall review
and approval process as well as enable a common development
programme across these countries. Further, a future study could
focus on developing proposals for an improved regulatory
model for approval and development of biosimilars in these
emerging economies. Integration of regulatory standards across
emerging economies would also enable streamlined biosimilar
development programmes and expedited licencing processes,
thereby facilitating improvements in patient care and access to
these life-saving medicines.
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